Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeRetia MedicalArgos Cardiac Output Patient Monitor Receives U.S. Food and Drug Administration Clearance

Argos Cardiac Output Patient Monitor Receives U.S. Food and Drug Administration Clearance

December 18, 2020

Argos Cardiac Output (CO) Monitor has received U.S. Food and Drug Administration 510k clearance and is now available for sale in the United States. The Argos CO monitoring device is intended for use on patients above the age of 18. It is intended to be used as a hemodynamic monitor for cardiac output monitoring and its derived parameters on patients in the intensive care unit or the operating room. (Retia Medical is a medical device company focused on advancing the quality and clinical use of hemodynamic monitoring).

The Retia Argos CO Monitor is highly accurate, easy-to-use and cost-effective. Equipped with the company’s proprietary Multi-Beat Analysis™ (MBA) Algorithm, it guarantees superior CO monitoring performance, quality, reliability, and compatibility for enhanced hemodynamic management.

“A key challenge in realizing the potential clinical benefits of CO monitoring is that many monitors fail to track CO changes accurately when fluid and vasoactive drug therapy are administered,” said Marc Zemel, S.M., M.B.A., co-founder and Chief Executive Officer of Retia Medical. “We designed Retia’s proprietary MBA™ algorithm to overcome the limitations of current CO monitoring technologies in order to realize the potentially life-saving benefits that accurate and effective hemodynamic management can provide to patients. With FDA clearance, the Argos CO Monitor is now available for sale in the United States and we are excited for the opportunity to advance CO monitoring as a strategy for improving patient outcomes.”

The company reports accurate CO monitoring can dramatically improve proactive clinical decision-making for high-risk surgical and critically ill patients and improves operating room (OR) and intensive care unit (ICU) outcomes. The Argos CO Monitor provides clinicians with the data required to track oxygen delivery and maintain optimal fluid status. Additionally, by eliminating disposable costs and integrating seamlessly with all vital signs monitors and common electronic medical record (EMR) systems, the Argos CO Monitor provides a simple and cost-effective solution to making CO monitoring broadly accessible in a greater number of care settings and making CO monitoring a standard of care for more patients.

Unique Features
In addition to its superior accuracy, key benefits of the Argos CO Monitor also include:

  • Enhanced ease of use – The Argos CO Monitor offers a patented, intuitive user interface that incorporates the streamlined design of consumer technology and offers user-friendly features. A single cable connection is all that is needed to acquire a blood pressure signal from any vital signs monitor. This facilitates set up and eliminates the need for user training.
  • Simple EMR connectivity – The Argos Monitor seamlessly integrates with EMR systems, providing immediate access to patients’ hemodynamic profiles from remote locations. With an open architecture and a vendor-agnostic design, hospitals aren’t locked into one proprietary system for data exchange. The Argos Monitor architecture ensures against obsolescence, providing a higher return on investment by eliminating the need for costly upgrades or system changes in the future.
  • Cost-effective – Without the need for costly disposables, the Argos Monitor can reduce five-year costs by more than 75% compared with other leading monitors.

*Argos cardiac monitor received FDA clearance in 2018.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy